Select a medication above to begin.
Talvey (talquetamab-tgvs)
talquetamab
Black Box Warnings .
Appropriate Use
restricted distribution program (TECVAYLI and TALVEY REMS) due to cytokine release syndrome (CRS) and neurological toxicity risk; administer only at certified healthcare facility with trained healthcare providers to manage CRS and neurological toxicities; 1-855-810-8064 or www.TEC-TALREMS.com for more information
Cytokine Release Syndrome
including fatal or life-threatening reaction occurred in 76% of patients; initiate tx according to step-up dosing schedule to decr. CRS risk; monitor patients x48h in hospital after each dose of step-up dosing schedule; manifestations may include fever, hypotension, chills, hypoxia, headache, tachycardia; provide supportive care as needed; withhold tx until signs/symptoms resolve or permanently D/C, based on severity
Neurological Toxicities
serious, life-threatening, or fatal reaction, including immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 55% of patients; may occur concurrently with CRS, after CRS resolution, or in the absence of CRS; monitor patients x48h in hospital after each dose of step-up dosing schedule; provide supportive care as needed; withhold tx until signs/symptoms resolve or permanently D/C, based on severity
Adult Dosing .
Dosage forms: INJ
Restricted Distribution in US
- [1-855-810-8064 or www.TEC-TALREMS.com for more information]
Special Note
- [drug name clarification]
- Info: nonproprietary name = talquetamab-tgvs
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing including toxicity-related dose adjustments
multiple myeloma, relapsed or refractory
- [0.01 mg/kg/dose SC x1 on day 1, then 0.06 mg/kg/dose SC x1 on day 4, then 0.4 mg/kg/dose SC x1 on day 7 as part of step-up dosing schedule, then 0.4 mg/kg/dose SC qwk starting day 14]
- Alt: 0.01 mg/kg/dose SC x1 on day 1, then 0.06 mg/kg/dose SC x1 on day 4, then 0.4 mg/kg/dose SC x1 on day 7, then 0.8 mg/kg/dose SC x1 on day 10 as part of step-up dosing schedule, then 0.8 mg/kg/dose SC q2wk starting day 24; Info: for patients refractory to at least 4 prior tx, including an anti-CD38 agent, a proteasome inhibitor, and an immunomodulatory agent
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.